.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,790,694

« Back to Dashboard

Details for Patent: 8,790,694

Title:Gastric retentive extended release pharmaceutical compositions
Abstract: The present disclosure provides extended release pharmaceutical compositions comprising an opioid and an additional active pharmaceutical ingredient, wherein the composition exhibits gastric retentive properties which are achieved by a combination of a physical property of the composition and release of the opioid, wherein upon administration to a subject, the composition has at least one pharmacokinetic parameter that differs by less than about 30% when the subject is in a fasted state as compared to a fed state.
Inventor(s): Devarakonda; Krishna R. (St. Louis, MO), Giuliani; Michael J. (Creve Coeur, MO), Gupta; Vishal K. (Hillsborough, NJ), Heasley; Ralph A. (Webster Groves, MO), Shelby; Susan (Town and Country, MO)
Assignee: Mallinckrodt LLC (Hazelwood, MO)
Filing Date:Dec 18, 2013
Application Number:14/132,500
Claims:1. A pharmaceutical composition, comprising: an immediate release portion comprising, by total weight of the immediate release portion, about 0.5% to about 2.5% of hydrocodone or a pharmaceutically acceptable salt of hydrocodone, and about 65% to about 85% of acetaminophen; and an extended release portion comprising, by total weight of the extended release portion, about 0.3% to about 1.0% of hydrocodone or a pharmaceutically acceptable salt of hydrocodone and about 15% to about 25% of acetaminophen; wherein the total amount of acetaminophen in the composition is about 200 mg to about 650 mg, and the total amount of hydrocodone or a pharmaceutically acceptable salt of hydrocodone in the composition is about 5 mg to about 15 mg; wherein when the composition is orally administered to a subject in need thereof the composition delivers the hydrocodone or the pharmaceutically acceptable salt thereof and the acetaminophen to the subject's upper gastrointestinal tract for at least about 4 hours to about 12 hours; and wherein either the hydrocodone or the acetaminophen produces a plasma profile characterized by at least one pharmacokinetic parameter selected from the group consisting of C.sub.max, C.sub.1 hr, C.sub.2 h, AUC, partial AUC, T.sub.max, and T.sub.lag that differs by less than about 30% when the subject is in a fasted state as compared to a fed state.

2. The pharmaceutical composition of claim 1, wherein the pharmacokinetic parameter selected from the group consisting of C.sub.max, C.sub.1 hr, C.sub.2 h, AUC, partial AUC, T.sub.max, and T.sub.lag differs by less than about 20%.

3. The pharmaceutical composition of claim 1, wherein the pharmacokinetic parameter is selected from the group consisting of AUC and C.sub.max.

4. The pharmaceutical composition of claim 1, wherein both the hydrocodone and the acetaminophen produce a plasma profile characterized by at least one pharmacokinetic parameter selected from the group consisting of C.sub.max, C.sub.1 hr, C.sub.2 h, AUC, partial AUC, T.sub.max, and T.sub.lag that differs by less than about 30% when the subject is in a fasted state as compared to a fed state.

5. The pharmaceutical composition of claim 1, wherein the composition is a bilayer tablet.

6. The pharmaceutical composition of claim 1, wherein the extended release portion comprises at least one extended release polymer.

7. The pharmaceutical composition of claim 6, wherein the at least one extended release polymer is a polyethylene oxide.

8. The pharmaceutical composition of claim 7, wherein the polyethylene oxide has a molecular weight from about 500,000 Daltons to about 10,000,000 Daltons.

9. The pharmaceutical composition of claim 6, wherein the at least one extended release polymer absorbs water and swells to a size sufficient for gastric retention.

10. The pharmaceutical composition of claim 1, wherein the total amount of the acetaminophen in the composition is about 325 mg; and the total amount of the hydrocodone or the pharmaceutically acceptable salt thereof in the composition is about 7.5 mg.

11. The pharmaceutical composition of claim 1, wherein the composition delivers the hydrocodone or the pharmaceutically acceptable salt thereof and the acetaminophen to the subject's upper gastrointestinal tract for at least about 6 hours.

12. The pharmaceutical composition of claim 1, wherein the composition comprises (a) two immediate release portions in which one of the immediate release portions contains the hydrocodone or the pharmaceutically acceptable salt thereof and the other immediate release portion contains the acetaminophen, and (b) two extended release portions in which one of the extended release portions contains the hydrocodone or the pharmaceutically acceptable salt thereof and the other extended release portion contains the acetaminophen.

13. The pharmaceutical composition of claim 1, wherein the composition is gastric retentive.

14. A pharmaceutical composition, comprising: at least one immediate release portion comprising hydrocodone or a pharmaceutically acceptable salt thereof and acetaminophen and at least one extended release portion comprising an extended release component, hydrocodone or a pharmaceutically acceptable salt thereof, and acetaminophen; wherein the at least one immediate release portion comprises from about 20% to about 30% (w/w) of the total amount of the hydrocodone or a pharmaceutically acceptable salt thereof, and about 40% to about 60% (w/w) of the total amount of the acetaminophen in the composition; wherein the at least one extended release portion comprises from about 70% to about 80% (w/w) of the total amount of the hydrocodone or a pharmaceutically acceptable salt thereof, and about 40% to about 60% (w/w) of the total amount of the acetaminophen in the composition; wherein the sum of the amounts of the acetaminophen in the immediate release and the extended release portions is about 325 mg; wherein the sum of the amounts of the hydrocodone or pharmaceutically acceptable salt thereof in the immediate release and extended release portions is about 7.5 mg; and wherein the bioavailability of the acetaminophen and the hydrocodone or the pharmaceutically acceptable salt thereof is not affected by the absence of food in a subject's gastrointestinal tract.

15. The pharmaceutical composition of claim 14, wherein when the pharmaceutical composition is administered to a subject under fasted conditions, the mean AUC for hydrocodone of the subject is about 9.0 nghr/mL/mg to about 24.0 nghr/mL/mg and the mean AUC for acetaminophen of the subject is about 35.0 nghr/mL/mg to about 80.0 nghr/mL/mg.

16. The pharmaceutical composition of claim 14, wherein when the pharmaceutical composition is administered to a subject under fasted conditions, the Cmax for hydrocodone of the subject is about 0.9 ng/mL/mg to about 2.0 ng/mL/mg and the Cmax for acetaminophen of the subject is about 6 ng/mL/mg to about 9 ng/mL/mg.

17. The pharmaceutical composition of claim 14, wherein the composition is a bilayer tablet.

18. A pharmaceutical composition, comprising: an immediate release portion comprising about 20% to about 30% (w/w) of the total amount of the hydrocodone or a pharmaceutically acceptable salt thereof in the composition, and about 40% to about 60% (w/w) of the total amount of the acetaminophen in the composition; and an extended release portion comprising about 70% to about 80% (w/w) of the total amount of the hydrocodone or a pharmaceutically acceptable salt thereof in the composition, and about 40% to about 60% (w/w) of the total amount of the acetaminophen in the composition; wherein the total amount of acetaminophen in the composition is about 200 mg to about 650 mg, and the total amount of hydrocodone or pharmaceutically acceptable salt thereof in the composition is about 5 mg to about 15 mg; wherein when the composition is orally administered to a subject in need thereof the composition delivers the hydrocodone or the pharmaceutically acceptable salt thereof and the acetaminophen to the subject's upper gastrointestinal tract for at least about 4 hours; and wherein either the hydrocodone or the acetaminophen produces a plasma profile characterized by at least one pharmacokinetic parameter selected from the group consisting of C.sub.max, C.sub.1 hr, C.sub.2 h, AUC, partial AUC, T.sub.max, and T.sub.lag that differs by less than about 30% when the subject is in a fasted state as compared to a fed state.

19. The pharmaceutical composition of claim 18, wherein the composition is a solid oral dosage form.

20. The pharmaceutical composition of claim 18, wherein the composition comprises about 325 mg of acetaminophen and about 7.5 mg of hydrocodone or pharmaceutically acceptable salt thereof.

21. The pharmaceutical composition of claim 18, wherein the composition further comprises at least one extended release polymer.

22. The pharmaceutical composition of claim 21, wherein the extended release polymer comprises a polymer selected from the group consisting of linear, branched, dendrimeric, or star polymers, hydrophilic polymers, and mixtures thereof.

23. The pharmaceutical composition of claim 18, wherein when the pharmaceutical composition is administered to a subject under fasted conditions, the mean AUC for hydrocodone of the subject is about 9.0 nghr/mL/mg to about 24.0 nghr/mL/mg and the mean AUC for acetaminophen of the subject is about 35.0 nghr/mL/mg to about 80.0 nghr/mL/mg.

24. The pharmaceutical composition of claim 18, wherein when the pharmaceutical composition is administered to a subject under fasted conditions, the Cmax for hydrocodone of the subject is about 0.9 ng/mL/mg to about 2.0 ng/mL/mg and the Cmax for acetaminophen of the subject is about 6 ng/mL/mg to about 9 ng/mL/mg.

25. The pharmaceutical composition of claim 18, wherein when the pharmaceutical composition is administered to a subject under fed conditions, the mean AUC for hydrocodone of the subject is about 9.0 nghr/mL/mg to about 24.0 nghr/mL/mg and the mean AUC for acetaminophen of the subject is about 35.0 nghr/mL/mg to about 80.0 nghr/mL/mg.

26. The pharmaceutical composition of claim 18, wherein when the pharmaceutical composition is administered to a subject under fed conditions, the Cmax for hydrocodone of the subject is about 0.9 ng/mL/mg to about 2.0 ng/mL/mg and the Cmax for acetaminophen of the subject is about 6 ng/mL/mg to about 9 ng/mL/mg.

27. A solid oral dosage form, comprising: an immediate release portion comprising about 20% to about 30% (w/w) of the total amount of the hydrocodone or a pharmaceutically acceptable salt thereof in the dosage form, and about 40% to about 60% (w/w) of the total amount of the acetaminophen in the dosage form; and an extended release portion comprising about 70% to about 80% (w/w) of the total amount of the hydrocodone or a pharmaceutically acceptable salt thereof in the dosage form, and about 40% to about 60% (w/w) of the total amount of the acetaminophen in the dosage form; wherein the total amount of hydrocodone or pharmaceutically acceptable salt thereof in the dosage form is about 7.5 mg and the total amount of acetaminophen in the dosage form is about 325 mg; wherein the dosage form has gastric retentive properties; and wherein the bioavailability of either the acetaminophen or the hydrocodone or the pharmaceutically acceptable salt thereof is not affected by the absence of food in a subject's gastrointestinal tract.

28. The solid oral dosage form of claim 27, wherein when the pharmaceutical composition is administered to a subject under fasted conditions, the mean AUC for hydrocodone of the subject is about 10.0 nghr/mL/mg to about 22.0 nghr/mL/mg and the mean AUC for acetaminophen of the subject is about 35.0 nghr/mL/mg to about 60.0 nghr/mL/mg.

29. The solid oral dosage form of claim 27, wherein when the pharmaceutical composition is administered to a subject under fasted conditions, the Cmax for hydrocodone of the subject is about 1.1 ng/mL/mg to about 2.0 ng/mL/mg and the Cmax for acetaminophen of the subject is about 6.5 ng/mL/mg to about 8.5 ng/mL/mg.

30. The solid oral dosage form of claim 27, wherein when the pharmaceutical composition is administered to a subject under fasted conditions, the Tmax for hydrocodone of the subject is about 2 hours to about 4 hours and the Tmax for acetaminophen of the subject is about 0.5 hours to about 4 hours.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc